This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Progenics Pharmaceuticals Inc (PGNX)

NASDAQ: Health Care

Company Income Statement
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Sales 44.38M 7.86M 14.05M 84.80M
Cost of Sales 357.00K 624.00K 499.00K 405.00K
Gross Operating Profit 44.02M 7.24M 13.55M 84.39M
Selling, General, and Administrative Expenses 14.94M 14.81M 14.71M 18.25M
Research & Development 28.23M 34.47M 33.01M 53.76M
Operating Income before D & A (EBITDA) 841.00K -42.04M -34.17M 12.38M
Depreciation & Amortization 545.00K 939.00K 1.32M 2.07M
Interest Income 51.00K 46.00K 60.00K 65.00K
Other Income - Net 7.25M 0.00 0.00 0.00
Special Income / Charges -4.18M 0.00 0.00 0.00
Total Income Before Interest Expenses (EBIT) 3.42M -42.93M -35.43M 10.38M
Interest Expense 0.00 0.00 0.00 0.00
Pre-Tax Income 3.42M -42.93M -35.43M 10.38M
Income Taxes -989.00K -362.00K 0.00 0.00
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations 4.41M -42.57M -35.43M 10.38M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations 4.41M -42.57M -35.43M 10.38M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income 4.41M -42.57M -35.43M 10.38M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
8.59M -42.57M -35.43M 10.38M
Preferred Dividends
Net Income Available To Common 4.41M -42.57M -35.43M 10.38M
Basic EPS from Continuing Ops. 0.06 -0.76 -1.02 0.31
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations 0.06 -0.76 -1.02 0.31
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total 0.06 -0.76 -1.02 0.31
Basic Normalized Net Income/Share 0.13 -0.76 -1.02 0.31
EPS fr Continuing Ops. 0.06 -0.76 -1.02 0.31
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. 0.06 -0.76 -1.02 0.31
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total 0.06 -0.76 -1.02 0.31
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0.13 -0.76 -1.02 0.31
Dividends Paid per Share 0.00 0.00 0.00 0.00
PGNX News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

PGNX Progenics Pharmaceuticals Inc

Chart of PGNX

Analysts Ratings for PGNX

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 2 2 2 2
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET PGNX ANALYST REPORT

PGNX Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs